Board of Pharmacy by Li, Jenny K.
HEALTH CARE REGULATORY AGENCIES
Board of Pharmacy
Executive Officer: Patricia Harris * (916) 445-5014 * Internet
ursuant to Business and Professions Code section 4000
et seq., the Board of Pharmacy grants licenses and per-
mits to pharmacists, pharmacy interns, pharmacy tech-
nicians, pharmacies, pharmacy corporations, nonresident
pharmacies, wholesale drug facilities, medical device retail-
ers, veterinary food-animal drug retailers, out-of-state dis-
tributors, clinics, and hypodermic needle and syringe distribu-
tors. It regulates all sales of dangerous drugs, controlled sub-
stances, and poisons. The Board is authorized to adopt regu-
lations, which are codified in Division 17, Title 16 of the
California Code of Regulations (CCR).
To enforce the Pharmacy Law and its regulations, the
Board employs full-time inspectors who investigate com-
plaints received by the Board. Investigations may be con-
ducted openly or covertly as the situation demands. The Board
conducts fact-finding and disciplinary hearings, and is au-
thorized by law to suspend or revoke licenses or permits for a
variety of reasons, including professional misconduct and any
misconduct substantially related to the practice of pharmacy.
The Board of Pharmacy is a consumer protection agency
located within the Department of Consumer Affairs (DCA).
The Board, which meets five
times per year, consists of eleven Obviously, a medicatio
members, four of whom arenonlcenses.The emaiing patient injury or death."nonlicensees. The remaining the Board on July 30 p
members are pharmacists, five of te toadon sec
whom must be active practitio- the CCR, which would 
ners. All Board members are ap- pharmacy to develop an
pointed for four-year terms. aracy togrameloOn May 21, Assemblyprogram toOn My 21 Assmbly errors attributable tc
Speaker Antonio Villaraigosa ap- personnel.
pointed Andrea Zinder as the
Board's newest public member;
Zinder replaces Kenneth Tait. Zinder is currently an execu-
tive assistant to the President of the United Food and Com-
mercial Workers Union Local 324, where she has worked since
1984. While working at UFCW, she has represented retail
workers and drugstore employees, including pharmacists, in
contract negotiations.
MAJOR PROJECTS
Prevention of Medication Errors:
Quality Assurance Program Regulations
The Board's primary responsibility is to protect the pub-
lic health, safety, and welfare of California's patients. The
Board has become increasingly concerned about the growing
incidence of medication errors [16:2 CRLR 55], which can
include any of the following: (1) the prescriber orders an in-
appropriate drug for a patient's condition; (2) incorrect infor-
www.dca.ca.govlpharmacy/
mation is entered on the label of the i t
prescription container; (3) a pre-
scription is dispensed with the wrong drug or wrong drug
dosage; (4) a drug is dispensed that is contraindicated if taken
with another drug; or (5) a prescription is filled with a medi-
cation whose expiration date has passed. Consistent problems
contributing to prescription errors are the absence or pres-
ence of computerized placeholders that are zeroes before and
after the decimal point in the dosage of a medication; misin-
terpreted abbreviations and incomplete medications; poor
communication (including illegible prescriber handwriting
[15:1 CRLR 87]); similarities in product names; ambiguities
in directions for use or medical abbreviations; unclear label-
ing; and poor pharmacy procedures or techniques. Some phar-
macists complain that their workload-the number of pre-
scriptions to be filled with insufficient staffing-may also
cause prescription errors.
Obviously, a medication error can result in patient injury
or death. To prevent such harm, the Board on July 30 pub-
lished notice of its intent to adopt new section 1717.5, Title 16
of the CCR, which would require every licensed pharmacy to
develop and implement a quality
n error can result in assurance program (QAP) to docu-
o prevent such harm, ment medication errors attributable
iblished notice of its to a pharmacy or its personnel. The
ion 1717.5,Title 16 of primary purpose of the QAP is not
2quire every licensed punitive; rather, it is to document
I implement a quality and analyze medication errors in
ocument medication order to enable the pharmacy to
a pharmacy or its take appropriate action to prevent
a recurrence. For purposes of the
required QAP, section 1717.5
would define the term "medication
error" as "any preventable event that may cause or lead to, or
that has caused or led to, inappropriate medication use or pa-
tient harm while the medication is in the possession of or un-
der the control of the pharmacy, another health care profes-
sional, or the patient or consumer. The circumstances or activi-
ties that may lead to or create a medication error include, but
are not limited to: receipt and use of health care products, in-
cluding drugs and devices; receipt of prescriptions, including
communication, interpretation, and evaluation of an order; drug
selection, compounding and dispensing, including direction and
supervision of pharmacy personnel; provision to patients, in-
cluding selection, preparation and labeling of the prescription
container, use of patient profiles, prescriber contacts, and pa-
tient consultation and education; patient use, including dispens-
ing and use of refills and monitoring of patient use; general
pharmacy administration, procedures, and systems; professional
pharmacy practice."
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Section 1717.5 would require every pharmacy to describe
its QAP in its policies and procedures manual, and would
specify the required contents of the QAP. At minimum, the
QAP analysis of medication errors must consider workplace
conditions, including general working conditions, peak
workload periods, and workplace design and operation; the
use of technology; and training and ongoing evaluation of
staff, including adequacy of training and evaluation to pro-
tect public health and safety. Section 1717.5 would require
each pharmacy to document in its QAP, for each medication
error, the fact that a QAP was con-
ducted; the findings and determi- Although many agreec
nations made by the pharmacy; QAP as an internal edu
and remedial efforts undertaken, the circumstances ar
if any, including communication opponents argued that'
to pharmacy personnel respon- of "medication error'
sible for the error and to pharmacy expressed concern abo
personnel in general. The phar- a pharmacy's QAP by
macy must maintain records of all
activities undertaken as part of its
QAP for at least three years, and make those records acces-
sible to the Board during normal business hours. The section
would also specify that compliance with the QAP require-
ment may be considered by the Board as a mitigating factor
in an investigation and evaluation of any medication errors.
On October 20, the Board held a public hearing on pro-
posed section 1717.5. Numerous pharmacists and represen-
tatives of pharmacies, retailers, and pharmaceutical compa-
nies registered opposition to the QAP requirement. Although
many agreed with the concept of a QAP as an internal educa-
tional tool to analyze the circum-
stances and reasons for errors, op-
ponents argued that the Absent new regulatio
provision's definition of"medica- SB 651 and the existi
tion error" is far too broad and require the closure o
expressed concern about the removal of all non-pha
discoverability of a pharmacy's the pharmacy area dui
QAP by plaintiff attorneys. Sev- and lunch periods wh
eral witnesses stated that the on January 1, 2000.
discoverability of a QAP in civil
litigation would discourage the re-
porting of errors, and argued that a pharmacy's QAP should
be immune from discovery in civil actions. Many opponents
stated that the focus should be on preventing errors instead of
reporting and investigating them after they occur; these op-
ponents argued that errors that are caught by pharmacy per-
sonnel before medication is dispensed to a consumer should
not have to be reported in the QAP. The California Pharma-
cists Association (CPhA) also argued that the Board should
reevaluate the fiscal impact of this proposal on pharmacies
subject to the QAP requirement.
After much debate and testimony at the October 20 hear-
ing, the Board unanimously deferred adoption of section
1717.5's current language and remanded this matter to its
Enforcement Committee for further study.
Emergency Regulations to Implement
SB 188 (Leslie): Pharmacy Operations
During Temporary Absence of a Pharmacist
At its October 20 meeting, the Board considered the
emergency adoption of new section 1714.1, Title 16 of the
CCR, to implement SB 188 (Leslie) (Chapter 900, Statutes
of 1999). SB 188 was amended late in the legislative year to
require the Board to adopt regulations accommodating the
temporary absence of a pharmacist from a pharmacy; SB 188
and the new regulations became
with the concept of a necessary after the Governor
ational tool to analyze signed SB 651 (Burton), which
reasons for errors, mandates breaks and lunch peri-
e provision's definition ods for pharmacists during the
is far too broad and workday (see LEGISLATION).
t the discoverability of Absent new regulations, the com-
aintiff attorneys. bination of SB 651 and the exist-
ing Pharmacy Law will require the
closure of a pharmacy and the re-
moval of all non-pharmacist personnel from the pharmacy
area during pharmacist breaks and lunch periods when SB
651 takes effect on January 1, 2000.
As drafted by the Board's Legislation and Regulation
Committee, emergency section 1714.1 would state that in
pharmacies staffed by a single pharmacist, the pharmacist may
leave the pharmacy temporarily for breaks and meal periods
without closing the pharmacy and removing ancillary staff
"if the pharmacist reasonably believes that the security of the
dangerous drugs and devices will be maintained in his or her
absence." If not, the pharmacy
area (the area in which prescrip-
., the combination of tion drugs and devices are kept)
g Pharmacy Law will must be closed and non-pharma-
a pharmacy and the cist employees must be removed
nacist personnel from during the pharmacist's absence.
ng pharmacist breaks Section 1714.1 would also state
SB 651 takes effect that during the pharmacist's ab-
sence, no prescription medication
may be provided to a patient or to
a patient's agent unless the pre-
scription medication is a refill that the pharmacist has checked,
released for furnishing to the patient, and was determined not
to require the consultation of a pharmacist.
Under the draft regulation, ancillary staff (including phar-
macy technicians and intern pharmacists) may continue to
perform nondiscretionary duties authorized by law during the
temporary absence of a pharmacist, but the pharmacist must
review any duty performed by ancillary staff upon his/her
return to the pharmacy. The proposal also states that in phar-
macies where two or more pharmacists are on duty, the phar-
macists must stagger their breaks and meal periods to ensure
that the pharmacy is not left without a pharmacist for a tem-
porary period. Finally, section 1714.1 would require pharma-
cies to draft written policies and procedures regarding the
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operation of the pharmacy during the temporary absence of
the pharmacist for breaks and meal periods.
Following its receipt of a number of comments from
pharmacist and labor organizations, the Board modified the
language of section 1714.1 to add a provision stating that "a
pharmacist who takes a break in compliance with this section
shall not be subject to California State Board of Pharmacy
disciplinary action or citation for acts that he or she did not
authorize and that he or she, by the exercise of reasonable
care, could not have prevented during his or her absence."
The Board adopted section 1714.1 as modified, and instructed
staff to forward the proposed emergency regulation to DCA
and the Office of Administrative Law (OAL) for approval.
At this writing, staff is preparing the rulemaking file on sec-
tion 1714.1; if approved by OAL, the emergency regulation
will be effective on January 1, 2000 for 120 days.
Waiver Requirements for Offsite
Storage of Drug Records
Business and Professions Code section 4081 requires
Board licensees to make available for Board inspection dur-
ing business hours all records of the manufacture, sale, ac-
quisition, or disposition of prescription drugs or devices.
Additionally, section 4105 requires "all records or other docu-
mentation of the acquisition and disposition of dangerous
drugs and dangerous devices by any entity licensed by the
Board... [to] be retained on the licensed premises in a readily
retrievable form," and section 4333 requires pharmacies to keep
records of all prescriptions filled on pharmacy premises and
available for inspection by Board personnel and other autho-
rized law enforcement officers for at least three years. How-
ever, subsections 4105(e) and 4333(c)(1) authorize the Board
to waive the onsite storage requirement upon written request.
In recent years, the Board has received an increasing num-
ber of applications for waiver of the onsite storage require-
ment, but has not granted any of
them. However, the Board realizes
that it is not always feasible or The Board realizes th
practical for a business to main- or practical for a bu
tain all of its records on the li- its records on the lice
censed premises, and seeks to to adopt regulatio
adopt regulations codifying stan- criteria by which it
dard criteria by which it would de- license holders might
termine which license holders ensuring that it is ab
might be granted a waiver, and en- action should a lice
suring that it is able to pursue dis- regarding records sto
ciplinary action should a licensee
violate its duties regarding records storage.
Thus, on May 21, the Board published notice of its in-
tent to adopt new section 1707, Title 16 of the CCR. Under
the proposed section, a waiver authorizing offsite storage of
drug records may be granted to a Board licensee if the lic-
ensee has no history of failure to produce records upon the
request of the Board or other law enforcement officer, no his-
tory of violations related to recordkeeping, and the licensee
is not on probation with the Board. Further, the storage area
must be maintained so that records are secure and the confi-
dentiality of any patient-related information is maintained;
the address of the site and the key to the storage area must
maintained on the licensed premises by an employee licensed
by the Board, and must be immediately accessible to the phar-
macist-in-charge and upon request to the Board or other law
enforcement officer; and the records in storage must be re-
trievable within two hours and at all times open to inspection
during business hours upon the request of the Board or other
law enforcement officer. Under the proposal, in the event that
a licensee fails to comply with the above provisions, the Board
may cancel the waiver without a hearing, at which time the
licensee must maintain all records at the licensed premises.
The proposal also specifies the method of reapplying for a
waiver in the event one has been canceled by the Board.
In its May 21 notice, the Board did not schedule a public
hearing on proposed section 1707, but several licensees re-
quested a hearing under Government Code section 11346.8(a).
On June 22, the Board issued a notice stating that it would
hold a public hearing on section 1707 at its July 28 meeting
in Burlingame. On July 7, the Board released a modified ver-
sion of section 1707, in which it added a new subsection to
the provision. The new language states that "notwithstanding
the requirements of this section, any entity licensed by the
Board may store the records described in subdivisions (a),
(b), and (c) of section 4105 of the Business and Professions
Code in a storage area at the same address or adjoining the
licensed premises without obtaining a waiver from the Board
if the following conditions are met: (1) the records are readily
accessible to the pharmacist-in-charge (or other pharmacist
on duty, or exemptee) and upon request to the Board or any
authorized officer of the law; and (2) the storage is main-
tained so that the records are secure and so that the confiden-
tiality of any patient-related information is maintained."
At the July 28 hearing, the
California Retailers' Association
it is not always feasible and Longs Drugs objected to the
ess to maintain all of two-hour requirement for records
ed premises,and seeks retrieval, arguing that the Board
codifying standard should consider a more reason-
uld determine which able time limit in light of poten-
granted a waiver, and tial traffic and other delays; Longs
to pursue disciplinary stated that the U.S. Drug Enforce-
ee violate its duties ment Administration (DEA) re-
ge. quires offsite records to be retriev-
able within 72 hours. CPhA ob-
jected to the regulations as unnecessary and expensive for
pharmacies; the trade association asserted that the legislative
history of the statutory waiver provisions was intended to
permit routine waivers of the onsite storage requirement, not
to require pharmacies to qualify for a waiver. CPhA called
for fairly automatic waivers upon request, and substantial sim-
plification of the regulatory language. Kaiser Permanente also
objected to the Board's proposal, noting that many hospitals
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do not have sufficient physical space for records storage.
Kaiser's records are stored in two centers where a pharmacist
is not in charge; rather, the records are maintained by a "pro-
fessional storage manager." Following the hearing, the Board
decided to substantially modify the language of section 1707
and to republish the section with its modifications.
On August 20, the Board published a revised version of
section 1707, Title 16 of the CCR. Under the August 20 lan-
guage, the Board "shall" grant a waiver of the onsite storage
requirement to any licensee for offsite storage of the records
described in Business and Professions Code subsections
4105(a), (b), and (c), unless the applicant has, within the pre-
ceding five years, failed to produce records pursuant to sec-
tion 4081 or has falsified records covered by section 4081.
However, even under this waiver, all prescription records must
be maintained on the licensed premises for a period of two
years from the date of dispensing. Any licensee granted a
waiver must maintain the offsite storage area so that the
records are secure, including from unauthorized access, and
must be able to produce the
records within 48 hours upon the Deputy Attorney Ge
request of the Board or other au- that other occupatiol
thorized law enforcement officer. used the citation and
The proposed regulation states for minor offenses,an
that if a licensee fails to comply being referred to theA
with these conditions, its waiver for full-blown adju
will be canceled without a hear- enforcement costs fo
ing (such that all records must be
maintained at the licensed pre-
mises), and provides a method of reapplying for another
waiver. Proposed section 1707 also expressly permits licens-
ees to store the records described in subdivisions (a), (b), and
(c) of section 4105 of the Business and Professions Code in a
storage area at the same address or adjoining the licensed
premises without obtaining a waiver from the Board if the
records are readily accessible to the pharmacist-in-charge (or
other pharmacist on duty, or exemptee) and upon request to
the Board or any authorized officer of the law, and the stor-
age is maintained so that the records are secure and so that
the confidentiality of any patient-related information is main-
tained.
The Board did not schedule another public hearing on
the revised language of section 1707, but accepted written
comments until October 4. At its October 20 meeting, the
Board discussed a comment received from Kaiser Permanente
calling for additional modifications to the language. The Board
took no action on section 1707 at its October meeting, and is
expected to revisit the proposal at its January 2000 meeting.
Citation and Fine Regulations
On May 21, the Board published notice of its intent to
amend section 1775 and 1775.1, Title 16 of the CCR, which
implement the Board's citation and fine authority under Busi-
ness and Professions Code sections 125.9 and 148. The pur-
poses of the amendments are to expand the listing of violations
subject to citation and fine to include noncompliance with the
Board's continuing education requirement, add violation of the
Board's regulations as a justification for the issuance of a cita-
tion and/or fine, and update the statutory references in the sec-
tions to reflect the 1996 reorganization of the Pharmacy Law.
The Board did not hold a public hearing on these pro-
posed amendments, but accepted written comments until July
5. At its July 28 meeting, the Board considered several com-
ments that it had received, and adopted the regulatory changes
subject to several minor revisions. The Board directed staff
to release the revised version of sections 1775 and 1775.1 for
an additional 15-day comment period, and then submit the
rulemaking file on the proposed changes to DCA and OAL
for approval.
In a related matter, at its October 20 meeting the Board
discussed staff's proposal to substantially expand its rather
narrow citation and fine regulations to permit the issuance of
citations and/or fines for violations such as abandonment of
a pharmacy, failure to produce records when requested by
the Board, absence of a pharma-
ral Bill Marcus noted cist from a pharmacy, failure to
licensing boards have notify the Board of a change of
e remedy expansively address, license lapse of phar-
he result is fewer cases macy technicians, and other rela-
orney General's Office tively minor violations. Deputy
ation (and reduced Attorney General Bill Marcus
noted that other occupational li-
censing boards have used the ci-
tation and fine remedy expan-
sively for minor offenses, and the result is fewer cases being
referred to the Attorney General's Office for full-blown adju-
dication (and reduced enforcement costs for such boards).
Following discussion, the Board approved staff's proposal;
at this writing, staff is drafting more expansive citation and
fine regulations for public notice and comment in the future.
Dangerous Drugs and Devices Exempt
From Storage in a Pharmacy
SB 1308 (Committee on Business and Professions)
(Chapter 655, Statutes of 1999) amended Business and Pro-
fessions Code section 4057 to remove from statute two lists
of dangerous drugs and devices that are exempt from the Phar-
macy Law's requirements and may be stored outside a
pharmacy's licensed premises when furnished to specified
licensed individuals or entities. Instead, SB 1308 directs the
Board to list these exempt drugs and devices in regulation.
Thus, on October 29, the Board published notice of its
intent to adopt section 1714.5, Title 16 of the CCR, to place
in regulation two lists of dangerous drugs and devices that
are exempt from required storage in a pharmacy, provided
they are obtained by a person or entity meeting specified li-
censure and practice criteria. Specifically, the section would
set forth a list of drugs and devices which need not be stored
in a licensed pharmacy so long as they have been sold or
furnished to a physician, dentist, podiatrist, pharmacist, medi-
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cal technician, medical technologist, optometrist, or chiro-
practor holding a currently valid and unrevoked license and
acting within the scope of his/her practice, or to a clinic, hos-
pital, institution, or establishment holding a currently valid
and unrevoked license or permit under specified sections of
the Health and Safety Code or the Welfare and Institutions
Code. Proposed section 1714.5 would also set forth a sepa-
rate list of drugs and devices which need not be stored in a
licensed pharmacy when a licensed home health agency or
hospice purchases, stores, furnishes, or transports them.
At this writing, the Board does not intend to hold a pub-
lic hearing on section 1714.5; however, it is accepting writ-
ten comments until December 13.
Update on Other Board Rulemaking
The following is an update on recent Board rulemaking
proceedings described in detail in Volume 16, No. 2 (Sum-
mer 1999) of the California Regulatory Law Reporter:
* Refill Pharmacy Regulations. Recently, many new
pharmacy operations and concepts have begun to emerge. One
such concept is a refill pharmacy, which prepares refill pre-
scriptions for another pharmacy. While the Board has licensed
such pharmacies in the past, it has determined that labeling
and documentation requirements should be established to
assure that patients can readily determine where the prescrip-
tion was filled. Thus, in February 1999, the Board published
notice of its intent to adopt section 1707.4, Title 16 of the
CCR, to address its concerns about the use of refill pharma-
cies. The purpose of the Board's proposal is to (1) allow a
pharmacy to utilize the services of another pharmacy to pro-
vide refills if it has a contract for these services or has com-
mon ownership; (2) specify the labeling requirements for a
prescription refilled at a refill pharmacy, including the name
of the refill pharmacy and which pharmacy the patient should
contact if he/she has questions (this information may be ei-
ther on the label or in writing ac-
companying the medication); (3) On May 20, the Boa
specify the documentation require- I783,Title 16 of the C
ments for the originating pharmacy of "authorized per
and the refill pharmacy; and (4) manufacturers and
allow a pharmacy to operate as a
refill pharmacy as well as fill new and Professions Cod(
prescriptions. [16:2 CRLR 50]
On May 19, the Board held a
public hearing on its proposed adoption of section 1707.4.
Most witnesses favored the proposal, although Steve Gray
from Kaiser Permanente clarified that three pharmacies may
be involved in a refill transaction-the pharmacy that receives
the refill request, the pharmacy that refills the prescription,
and the pharmacy that gives the refilled prescription to the
patient. He recommended that the language of section 1707.4
be modified to require that only the name and address of the
pharmacy that refills the prescription appear on the prescrip-
tion container label. Following public comment mostly in
support of the proposal, the Board adopted the section
subject to several minor modifications. Specifically, the Board
amended the section to require the prescription container to
be clearly labeled with all information required by Business
and Professions Code section 4076, plus the name and ad-
dress of the pharmacy refilling the prescription and/or the
name and address of the pharmacy that receives the refilled
prescription for dispensing to the patient.
On June 3, Board staff released the modified version of
section 1707.4 for an additional 15-day comment period end-
ing June 21. At this writing, DCA is considering the
rulemaking file on section 1707.4; after DCA approves the
file, it will be forwarded to OAL for approval.
* Medical Device Retailer Location Restrictions. On
May 20, the Board adopted new section 1748.3, Title 16 of
the CCR, which explicitly prohibits a medical device retailer
from conducting business from a private residence and from
locating a warehouse, the primary purpose of which is stor-
age of medical devices, at a private residence. Under Busi-
ness and Professions Code section 4132(0, medical device
retailers are required to make their records of sale, purchase,
and disposition of dangerous devices available, at all times
during business hours, for inspection by authorized law en-
forcement officers. When persons conduct a medical device
retail business from their home or the home of someone else,
Pharmacy Board inspectors and authorized law enforcement
officers have encountered problems gaining access to records
because of residential privacy issues. The new regulatory sec-
tion eliminates this problem. [16:2 CRLR 50] At this writing,
DCA is considering the rulemaking file on section 1748.3;
after DCA approves the file, it will be forwarded to OAL for
approval.
* Furnishing of Drugs andDevices by Wholesalers and
Manufacturers. On May 20, the Board adopted new section
1783, Title 16 of the CCR, to clarify the identity of"autho-
rized persons" to whom drug manufacturers and wholesalers
may furnish dangerous drugs and
devices under Business and Pro-
,ta t ne section fessions Code section 4163. [16:2
nto clarifythe identity CRLR 50-51] Under section
ons" to whom drug 1783, the term "'authorized per-
eviesuder ma urins son" means a person to whom the
i nder Busines Board has issued a permit which
enables the permit holder to pur-
chase dangerous drugs or devices
for use within the scope of its permit. "Authorized person"
also means any person in California or in another jurisdiction
within the United States to the extent such furnishing is au-
thorized by the law of this state, any applicable federal law,
and the law of the jurisdiction in which that person is located.
The manufacturer or wholesaler furnishing to such a person
shall, prior to furnishing the dangerous drugs and devices,
establish that the intended recipient is legally authorized to
receive the dangerous drugs or devices. The section is in-
tended to eliminate any confusion on the part of drug whole-
salers and manufacturers regarding with whom they may make
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arrangements for the purchase and delivery of drugs, and to
ensure that these drugs are maintained at all times by licens-
ees or their designated agents. OAL approved the new sec-
tion on August 25.
Pharmacy Practice on the Internet
At its October 20 meeting, the Board discussed draft leg-
islation to address the recent and potentially dangerous pro-
liferation of pharmacy practice activity on the Internet. Al-
though the Pharmacy Law requires an Internet pharmacy
which offers to compound, dispense, or refill a prescription
for a resident of California to be
licensed by the Board as a non- Although the Phar
resident pharmacy (such that the Internet pharmacy w
Board has disciplinary jurisdic- dispense, or refill a pr
tion over it), enforcement of that of California to be lic
requirement in the Internet envi- nonresident pharma
ronment is difficult. Although the has disciplinary j
Board's Licensing Committee has enforcement of th2
requested that the Board sponsor Internet environmen
legislation to regulate Internet
pharmacy practice and Deputy
Attorney General Bill Marcus has attempted a draft, the
Committee's study thus far has resulted in conclusions simi-
lar to those reached by the Medical Board's Committee on
Internet Prescribing: Internet practice is a global problem,
far bigger than any state licensing board or even federal agency
can address. Perhaps the most any state agency can do is edu-
cate consumers to exercise extreme caution when purchasing
dangerous drugs or devices over the Internet (see agency re-
port on MEDICAL BOARD OF CALIFORNIA for related
discussion).
The legislation drafted by Marcus and considered by the
Board in October would establish the following requirements
for an out-of-state Internet pharmacy dispensing prescription
drugs to California residents: (1) it must be licensed by the
Board as a nonresident pharmacy,
and must be licensed as a phar-
macy in its home state; (2) it may Some Internet pharn
not be foreign-based or owned by and run by responsibl
prescribers; (3) it may not offer by the Board's laws
prescribing-based sites where the Board realizes that it
prescriber issues a prescription to so as not to impede I
a consumer based upon an online entrepreneurs.
questionnaire; (4) it may only ac-
cept a faxed prescription from a prescriber (it may also re-
ceive a faxed prescription from a patient, but must receive
the original prescription from the patient prior to filling the
prescription); (5) it must disclose on its homepage its name,
location, toll-free number, and California license number; and
(6) it must be registered with the Verified Internet Pharmacy
Practice Site (VIPPS) program administered by the National
Association of Boards of Pharmacy. NABP has developed
the VIPPS program to certify Internet pharmacy sites if they
meet certain criteria, similar to a "Good Housekeeping" seal
of approval. Further, Marcus' draft statutory language would
provide the Board with the ability to impose civil penalties
against Internet pharmacies that do not comply with this
legislation.
The Board acknowledges that many consumers prefer to
purchase prescription drugs over the Internet because of the
convenience, access, and occasional cost savings. Some
Internet pharmacy sites are safe, secure, and run by respon-
sible pharmacists who abide by the Board's laws and regula-
tions, and the Board realizes that it must proceed cautiously
so as not to impede lawful commerce by these entrepreneurs.
However, other pharmacy sites
are seeking only to make a quickacy Law requires an
h offers to compound, profit, and can easily shut down
cription for a resident (and reopen almost instantly un-
sed by the Board as a der another address) if any gov-
(such that the Board ernment agency seeks to investi-
isdiction over it), gate them. The VIPPS program
requirement in the may enable consumers to tell the
difficult, difference; however, consumers
must be educated to expect and
demand such information. Thus,
the industry and the Board must educate consumers about
how to safely use the Internet to purchase drugs. Following
discussion, the Board agreed that its Licensing Committee
and its Legislation and Regulation Committee should take
another look at the proposed legislation, circulate it to inter-
ested parties, and incorporate appropriate changes before any
decision is reached on its introduction.
Implementation of the FDA
Modernization Act of 1997
The FDA Modernization Act of 1997, which became ef-
fective in November 1998, requires the U.S. Food & Drug
Administration (FDA) and the fifty states to enter into a
memorandum of understanding (MOU) regarding the com-
pounding of drugs. Compounding
is the process by which a phar-
y sites are safe,secure, macist combines, mixes, or alters
harmacists who abide ingredients to specialize a medi-
i regulations, and the cation for a patient, at the direc-
Ist proceed cautiously tion of a physician. Section 503A
rul commerce by these of the Act recognizes compound-
ing as an element of the practice
of pharmacy that is to be regu-
lated by the states, and distinguishes it from "manufactur-
ing" which falls within the jurisdiction of the FDA. The pur-
pose of the section is to ensure continued availability of com-
pounded drug products as a component of individualized
therapy, while limiting the scope of compounding so as to
prevent manufacturing under the guise of compounding." The
purpose of the MOU is to address the interstate distribution
of "inordinate amounts" of compounded drug products and
the related issue of state investigations of complaints regard-
ing this distribution.
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The law instructs the FDA to promulgate regulations
establishing the parameters of the MOU, and to consult with
the National Association of Boards of Pharmacy (NABP) to
develop a standard MOU for state boards. The goal of the
MOU is to obtain state agreement on two issues: (1) proto-
cols for the appropriate investigation of complaints relating
to compounded drug products shipped out-of-state; and (2)
establishment of appropriate restrictions on the amount of
compounded drugs shipped in interstate commerce, includ-
ing "safe harbors" for pharmacists who distribute com-
pounded products in interstate commerce. Pharmacies lo-
cated in a state that did not sign an MOU by the law's effec-
tive date (November 21, 1998) are subject to FDA's "safe
harbor" provision, whereby com-
pounded products may not ex-
ceed 5% of the total prescription The Board stressed th
orders dispensed or distributed by on what the compour
that pharmacy. [16:2 CRLR 51; how it does it, not ho'
16:1 CRLR 71-72] words, the regulatio
In January 1999, FDA pub- quality of the pha
lished draft regulations and a compounded, not thi
draft MOU which have been
greeted by opposition from compounders and state boards
alike. Among other things, the draft MOU requires the Board
to agree to take action against a pharmacy that engages in
the interstate distribution of compounded drugs under ei-
ther of the following circumstances: (1) the number of com-
pounded prescriptions dispensed or distributed interstate
annually by the pharmacy is equal to or greater than 20% of
the total number of prescriptions dispensed or distributed
(including both intrastate and interstate) by that pharmacy;
or (2) the number of compounded prescriptions dispensed
or distributed interstate annually by a pharmacy is less than
20% of the total number of prescriptions dispensed or dis-
tributed (including both intrastate and interstate) by that
pharmacy, but prescriptions for one or more individual com-
pounded drug products (including various strengths of the
same active ingredient) dispensed or distributed interstate
constitute more than 5% of the total number of prescrip-
tions dispensed or distributed. Compounded drugs that are
distributed interstate but "locally" are excluded from the
calculation to determine the number of compounded pre-
scriptions dispensed or distributed annually by a pharmacy,
but the MOU defines the term "locally" to mean distribu-
tion by a pharmacy to patients located within 50 miles of
the pharmacy (notwithstanding that such patients live in
another state)-thus requiring compounding pharmacies to
keep close track of the mileage between their address and
the address of their patients. Apparently, pharmacies that
exceed the 20% limit must be licensed by FDA as manufac-
turers.
At its July 28 meeting, the Board heard extensive pub-
lic comment from compounding pharmacies and reviewed
other written comments that national compounding asso-
ciations have submitted to FDA. The compounding phar-
macies, largely small specialist pharmacies, complained that
both the 5% "safe harbor" and the 20% "inordinate" limits
are arbitrary, and that the 20% limit will not allow their phar-
macies to remain financially viable or serve patients who
benefit from their specialized practices. These compound-
ing pharmacies also noted that the MOU has no effect on
chain pharmacies with outlets in multiple states; the com-
pounding pharmacies contended that, because of their many
locations and large volume of prescriptions orders, inter-
state chain pharmacies are being granted a monopoly on
compounded drugs.
Following public comment and discussion, the Board de-
cided to write a letter to FDA objecting to both the 20% an-
nual limitation on compounded
drugs distributed interstate and the
the MOU should focus 50-mile geographic restriction.
nig pharmacy does and The Board stressed that the MOU
much it does; in other should focus on what the com-
should focus on the pounding pharmacy does and how
iaceutical products it does it, not how much it does;
uantity. in other words, the regulations
should focus on the quality of the
pharmaceutical products compounded, not the quantity. At
this writing, the FDA has neither adopted final implementing
regulations nor released a final MOU; once FDA releases the
MOU, the Board must decide whether to sign it.
LEGISLATION
SB 1308 (Committee on Business and Professions), as
amended September 2, enacts various technical changes af-
fecting licensing boards within DCA. Several of the bill's
provisions amend the Pharmacy Act in the Business and Pro-
fessions Code, including the following:
- The bill amends section 4022 to revise the definition
of "dangerous drug or device" to include drugs or devices
bearing the statement "Rx only." This change conforms
California's definition of "dangerous drug or device" to the
federal definition.
- SB 1308 amends section 4043 and adds section 4040.5
to the Code to clarify that "reverse distributors" (companies
that remove outdated/non-saleable drug products from phar-
macies for disposal) and brokers (those who arrange for the
sale of drugs but may not take actual possession of the drugs)
must be licensed as drug wholesalers by the Board.
- The bill amends section 4057 to permit the Board to
control through regulations (rather than statute) two lists of
dangerous drugs and devices that may be stored outside a
pharmacy's licensed premises when dispensed or furnished
to specific licensed individuals or entities. The Board is al-
ready engaged in rulemaking to adopt regulations containing
these lists (see MAJOR PROJECTS).
- SB 1308 amends section 4078 to permit a pharmacist
to place a false label on a prescription if the labeling is a
necessary part of a clinical or investigational drug program
approved by the FDA or a legitimate investigational drug
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project involving a drug previously approved by the FDA.
The bill also permits false labeling in situations where, in the
medical judgment of the prescriber, the labeling is necessary
for the proper treatment of the patient.
- The bill amends section 4102 to specify that a pharma-
cist may perform skin puncture in the course of routine pa-
tient assessment procedures.
0 SB 1308 amends section 4115.5 to extend the period
of time allowed for practical experience in a pharmacy from
six months to one year for pharmacy technician trainees en-
rolled in training programs run by private or public schools.
* The bill amends section 4200.5 to clarify that those
seeking a retired pharmacist's license need not surrender their
original wall certificate to the Board in order to retire their
license.
* SB 1308 also amends section 4202 to require an appli-
cant for registration as a pharmacy technician to be a high
school graduate or to possess a general education develop-
ment equivalent.
- The bill amends section 4402 to provide that the Board
may cancel any license that is not renewed within 60 days
after its expiration.
, Finally, SB 1308 amends section 11165 of the Health
and Safety Code to expand the Controlled Substance Utiliza-
tion Review and Evaluation System (CURES) program to
include statistical analysis, education, and research, and ex-
tend CURES until July 1, 2003. CURES was created in 1997
as a three-year pilot project to electronically monitor the pre-
scribing and dispensing of Schedule II controlled substances
by all practitioners authorized to
prescribe or dispense them.
CURES will eventually replace
the paper-intensive "triplicate"
system currently used to track the
prescription and dispensing of
Schedule II narcotics. While still
in the pilot project phase, CURES
is being administered concurrently
Under SB 651, pharm
exempt as "professional'
be afforded breaks and
they are specifically exenm
or "executive" staff.
with the existing tripli-
cate system, to examine the comparative efficiencies between
the two systems. [16:2 CRLR 48-49; 16:1 CRLR 69-70] SB
1308 also requires the Department of Justice, in consultation
with the Board, to submit reports to the legislature on the
effectiveness of the CURES program on January 1, 2000,
2001, and 2002.
SB 1308 was signed by the Governor on October 6 (Chap-
ter 655, Statutes of 1999).
AB 261 (Lempert). Existing law authorizes a pharma-
cist to perform certain patient management functions (e.g.,
ordering or performing routine patient assessment procedures
such as temperature, pulse, and respiration; ordering drug
therapy-related laboratory tests; administering drugs and
biologicals by injection; and adjusting the drug regimen of a
patient) as part of the care provided by a health care facility,
a licensed home health agency, a licensed clinic, or a pro-
vider under contract with a health care service plan, in accor-
dance with written policies, procedures, or protocols of that
facility, home health agency, licensed clinic, or health care
service plan. As amended July 7, AB 261 additionally autho-
rizes a pharmacist to perform those procedures or functions
in any setting in accordance with the policies, procedures, or
protocols of a physician. The bill also revises the standards
for those policies, procedures, and protocols to require that,
at a minimum, they require that the medical records of the
patient be available to both the patient's prescriber and the
pharmacist, and that the procedures to be performed by the
pharmacist relate to a condition for which the patient has first
been seen by a physician.
AB 261 was sponsored by CPhA and supported by the
Board. The California Medical Association originally opposed
the bill, but CPhA worked with CMA to amend the bill to
resolve its concerns. Governor Davis signed AB 261 on Sep-
tember 15 (Chapter 375, Statutes of 1999).
SB 651 (Burton), as amended June 22, provides that a
person employed in the practice of pharmacy is not exempt
from the coverage of the orders of the Industrial Welfare Com-
mission unless he/she individually meets the criteria estab-
lished for exemption as an executive or administrative em-
ployee. The bill further provides that no person employed in
the practice of pharmacy may be subject to any exemption
from the coverage of the orders of the Industrial Welfare Com-
mission established for professional employees.
Prior to this bill, pharmacists were considered "profes-
sional" employees and were exempt from IWC orders requir-
ing mandatory breaks and lunch periods for employees. The
proponents of SB 651 argued that
the exemption imposed signifi-
acists are no longer cant hardship on pharmacists,
emncp ios n us who routinely work twelve-hour
ln per"adiodstrunves days and are frequently denied
pt as "administrative" breaks or lunch periods, simply
because they are licensed by the
State of California. Under SB 651,
pharmacists are no longer exempt as "professional" employ-
ees, and must be afforded breaks and lunch periods unless
they are specifically exempt as "administrative" or "'execu-
tive" staff.
Without additional changes to existing law, the passage
of SB 651 would have required the physical closing of phar-
macies (at least the area in which prescription medications
are kept), as well as the removal of all non-pharmacist staff,
during these temporary absences of a licensed pharmacist.
Thus, the enactment of SB 651 prompted amendments to SB
188 (Leslie), which now requires the Board to adopt regula-
tions governing the functioning of a pharmacy and the work
of pharmacy technicians while a pharmacist is temporarily
absent from the licensed premises (see below). Governor
Davis signed SB 651 on July 26 (Chapter 190, Statutes of
1999).
SB 188 (Leslie). Existing law authorizes a pharmacy tech-
nician to perform nondiscretionary tasks only while assisting
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and while under the direct, immediate, and personal super-
vision and control of a pharmacist. Any pharmacist respon-
sible for a pharmacy technician must be on the premises at
all times and the pharmacy technician must be within the
pharmacist's view, except when the pharmacy technician is
employed to assist in the filling of prescriptions for an inpa-
tient of a hospital or for an inmate of a correctional facility.
As amended September 7, SB 188 requires the Board-not-
withstanding the above limitations-to adopt regulations to
accommodate the temporary absence of a pharmacist for
breaks and lunch periods pursuant to Labor Code section
512 and the orders of the Industrial Welfare Commission
without closing the pharmacy. This change was prompted
by SB 651 (Burton), which mandates breaks and lunch pe-
riods for most pharmacists (see above). During temporary
pharmacist absence, a pharmacy technician may remain in
the pharmacy but may only perform nondiscretionary tasks;
the pharmacist remains responsible for the pharmacy tech-
nician and must review any task performed during the
pharmacist's temporary absence. The Board recently adopted
emergency regulations to implement this provision of SB
188 (see MAJOR PROJECTS).
Existing law generally prohibits any person from sell-
ing or dispensing any dangerous drug, or dispensing any
prescription, unless he/she is a licensed pharmacist. How-
ever, a licensed hospital that contains 100 beds or fewer
and does not employ a full-time pharmacist may purchase
drugs at wholesale for administration, under the direction
of a physician, to patients registered in the hospital or to
emergency cases under treatment in the hospital. These hos-
pital drug dispensing activities operate under a so-called
"limited drug room license." SB 188 authorizes hospitals
that have a limited drug room license and that meet the statu-
tory definition of a "small and rural hospital" to dispense
drugs to outpatients under limited circumstances, and
defines those circumstances. The bill is designed to assure
patients in rural areas that their needs for medication can be
met in a reasonable manner. SB 188, an urgency bill, was
signed by the Governor on October 9 (Chapter 900, Stat-
utes of 1999) and took effect on that date.
AB 724 (Dutra), as amended September 7, is the "Year
2000 Problem Good Government Omnibus Act of 1999," and
is intended to address problems that may arise from Y2K com-
puter failures. Among other things, AB 724 provides that,
notwithstanding any other provision of law, during the pe-
riod commencing December 1, 1999, and ending February 1,
2000, a pharmacist may refill any refillable prescription sub-
ject to the number and terms of authorized refills, upon re-
quest of the person on whose behalf the prescription was writ-
ten, provided (1) the prescriber is unavailable to authorize
the early dispensing of the medication refill, and (2) the refill
medication dispensed does not exceed the dosage prescribed
to sustain the patient with uninterrupted therapy during this
period. The Governor signed AB 724 on October 7 (Chapter
784, Statutes of 1999).
SB 816 (Escutia). Existing law permits a nurse practi-
tioner (NP) to "furnish" prescription drugs and devices, in
accordance with standardized procedures developed by the
NP and his/her supervising physician, under specified circum-
stances; the term "furnish" is defined as the ordering of a
drug or device in accordance with the standardized proce-
dure, and transmitting an order of a supervising physician.
Existing law also permits a physician assistant (PA), under
specified circumstances and while under the supervision of a
physician, to administer or provide prescription drugs to a
patient, or transmit orally or in writing on a patient's record
or transmittal order, a prescription to a person who may law-
fully furnish the medication. SB 816 adds "ordering" pre-
scription drugs and devices to existing provisions of law per-
mitting NPs and PAs to "furnish" or "transmit" drugs and
devices in accordance with procedures developed by the NP
or PA and his/her supervising physician. SB 816 also requires
all NPs and PAs who are authorized to furnish or issue drug
orders for controlled substances to register with the DEA.
This bill also defines the term "drug order" as an order
for medication which is dispensed to or for a patient, issued
by a NP or PA as an individual practitioner, within the mean-
ing of the Code of Federal Regulations; and specifies that a
drug order issued by a NP or PA shall be treated in the same
manner as a prescription of the supervising physician. Finally,
the bill provides that all references to the term "prescription"
in the Business and Professions Code and the Health and
Safety Code shall include drug orders issued by NPs or PAs,
and deems the signature of a NP or PA on a drug order to be
the signature of a prescriber for purposes of the Business and
Professions Code and the Health and Safety Code (thus au-
thorizing pharmacists to fill them). This bill was signed by
the Governor on October 7 (Chapter 749, Statutes of 1999).
AB 1545 (Correa), as amended September 3, expands
and clarifies existing law that permits NPs and PAs to furnish
prescriptions for medicine that are within standardized pro-
cedures, as long as certain conditions are met. Specifically,
AB 1545 permits a NP who is functioning pursuant to a stan-
dardized procedure or protocol, or a PA functioning under
the supervision of a physician, to hand to a patient of the
supervising physician a prescription drug prepackaged by a
physician, a manufacturer, or a pharmacist; and requires, if
applicable, that the name of the NP or PA appear on the con-
tainer label of any such prescription. The bill also permits a
NP or PA to sign for the delivery of a complimentary sample
of a dangerous drug or device, and adds the Board of Regis-
tered Nursing and the Physician Assistant Committee to the
list of regulatory bodies to which the Board of Pharmacy is
required to forward all complaints related to the dispensing
of dangerous drugs or devices. This bill was signed by the
Governor on October 9 (Chapter 914, Statutes of 1999).
SB 838 (Figueroa), as amended April 28, allows the
Board to register a nonresident pharmacy that is organized as
a limited liability company (LLC) in the state in which it is
licensed. Merck-Medco Managed Care sponsored this bill to
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clarify that the Board may continue its longstanding practice
of registering nonresident pharmacies that are organized as
LLCs in their home states. An LLC-a hybrid between a part-
nership and a corporation-is a relatively new form of busi-
ness organization in California. The Board registered out-of-
state LLC pharmacies at least through 1997. At that time,
DCA analyzed some uncodified language in the LLC law
which prohibits the organization of an LLC for the rendering
of professional services. Based on DCA advice, the Board
began to reject licensure applications from out-of-state LLC
pharmacies. [16:1 CRLR 70-71] The sponsor and its sup-
porters maintain that this bill clarifies ambiguity created by
issuance of various legal opinions on the topic, and that cer-
tainty in the law is necessary in order to continue to provide
low-cost mail order medications. Governor Davis signed SB
838 on July 6 (Chapter 73, Statutes of 1999).
AB 1430 (Bates), as amended September 9, would have
made a number of changes relating to the prescription and re-
ceipt of drugs by Board licensees. First, it would have elimi-
nated an existing prohibition and provided that dangerous drugs
or devices may be furnished without a prescription to a profes-
sional corporation, partnership, or other entity comprised of
licensed health care professionals who are lawfully able to re-
ceive these drugs, provided that specified criteria and proce-
dures are met. Further, the bill would have eliminated an exist-
ing requirement that electronic data transmission prescriptions,
as defined, be reduced to writing by the pharmacist.
The Board worked with the bill's author and sponsor,
Kaiser Permanente, to resolve many concerns about AB 1430,
and all of the Board's requested changes were amended into
the bill. However, an eleventh-hour amendment to the bill
would have restricted the Board's authority to regulate drug
wholesalers by precluding it from enforcing new section 1783,
Title 16 of the CCR, for at least one year (see MAJOR
PROJECTS); thus, the Board opposed the bill. The Attorney
General's Office also opposed AB 1430, arguing that it would
(1) inappropriately broaden the authority of manufacturers
and wholesalers to provide dangerous drugs and devices, (2)
diminish the authority of the Board of Pharmacy to closely
monitor the acquisition and maintenance of such drugs by
providers, and (3) fail to provide strict policies and proce-
dures for identification of those authorized to obtain danger-
ous drugs. On October 10, Governor Davis agreed with the
Board and the AG and vetoed AB 1430, expressing concern
that "this bill could create avenues for the illicit diversion of
controlled substances" and urging the author to work with
the Attorney General on crafting a product that eliminates
this potential. Because the Governor vetoed AB 1430, regu-
latory section 1783 is now in effect.
AB 141 (Knox), as amended August 16, would require
the Board to conduct a study of the incidence of medication
errors in pharmacies in California, and report its findings to
the legislature by December 1, 2004. [S. Appr]
AB 1496 (Olberg), as amended September 10, is no
longer relevant to the Board of Pharmacy. Prior versions of
the bill would have added section 4052.5 to the Business and
Professions Code to establish a new "home medical equip-
ment services provider" licensure category under the Board
to replace the "medical device retailer" category, and ex-
panded the definition of those who must be licensed as home
medical equipment services providers.
AB 660 (Cardenas), as amended April 28, is also a Y2K
bill authorizing pharmacists to refill prescriptions between
November 1, 1999 and February 29, 2000 under certain cir-
cumstances (see above). [S. B&P]
SB 404 (Alpert), as amended in March 1999, would au-
thorize a pharmacist to initiate emergency contraception drug
therapy in accordance with written guidelines or protocols
previously established and approved for his/her practice by a
practitioner authorized to prescribe drugs. [S. B&P]
RECENT MEETINGS
At its May 20 meeting in San Diego, the Board elected
pharmacist Richard Mazzoni as its president, public member
Robert Elnser as vice-president, and public member Caleb
Zia as treasure.
At its May and July meetings, the Board discussed its on-
going difficulty in retaining experienced and qualified inspec-
tors, pharmacists who are employed by the Board to investi-
gate consumer and other complaints made to the Board about
licensees. At the May meeting, Executive Officer Patty Harris
reported that eight of the Board's 19 inspector positions were
vacant; by the July meeting, 10 of the 19 inspector positions
were vacant. The high attrition rate in Board inspector posi-
tions has been a serious problem since 1994, and is due in large
part to the low salary paid to Board inspectors. According to
Harris, the gap between Board inspector salaries and private
sector pharmacist positions is about $20,000; there is even a
substantial gap between the salary of Board inspectors and simi-
lar positions at other state agencies, which makes it very diffi-
cult for the Board to recruit and retain inspectors. Unfortu-
nately for the Board, a provision in early versions of SB 1308
(Committee on Business and Professions) (Chapter 655, Stat-
utes of 1999) requiring the salary of the Board's pharmacist
inspectors to be within 5% parity of pharmacists employed by
the University of California [16:2 CRLR 52] was deleted on
August 30 due to opposition by the Davis administration's
Department of Personnel Administration (DPA). However,
according to a Board memorandum distributed on October 12,
DPA has agreed to provide Board inspectors with a 10% aug-
mentation in addition to the 4% increase for state employees.
Hopefully, this increase will stem the tide of vacancies and
permit the Board to shore up its staff of inspectors.
FUTURE MEETINGS
" January 25-27,2000 in Riverside.
" April 12-13, 2000 in Sacramento.
" July 25-26,2000 in San Diego.
" October 18-19,2000 in San Francisco.
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